PT  - JOURNAL ARTICLE
AU  - Guimarães, Luiz F. F.
AU  - Rodrigues, Bárbara A.
AU  - Dias, Michelle H. F.
AU  - Barcelos, Matheus G.
AU  - Nascimento, Maria F. A.
AU  - Moreira-Nascimento, Sâmick L.
AU  - Afonso, Sofia L.
AU  - Abreu, Barbara G. S.
AU  - Middeldorp, Jaap. M.
AU  - Ntumngia, Francis B.
AU  - Adams, John H.
AU  - Fabbri, Camila
AU  - Lopes, Stefanie
AU  - Fernandes, Cor J. F.
AU  - Kano, Flora S.
AU  - Carvalho, Luzia H.
TI  - Antibody response to <em>Plasmodium vivax</em> in the context of Epstein-Barr virus (EBV) co-infection: A 14-year follow-up study in the Amazon rainforest
AID  - 10.1101/2024.09.25.24314386
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.09.25.24314386
4099  - http://medrxiv.org/content/early/2024/09/27/2024.09.25.24314386.short
4100  - http://medrxiv.org/content/early/2024/09/27/2024.09.25.24314386.full
AB  - Background To develop an effective vaccine against Plasmodium vivax, the most widely dispersed human malaria parasite, it is critical to understand how coinfections with other pathogens could impact malaria-specific immune response. A recent conceptual study proposed that Epstein-Barr virus (EBV), a highly prevalent human herpesvirus that establishes lifelong persistent infection, may influence P. vivax antibody responses. Here, it was investigated whether EBV could impact the longevity of humoral immune response to P. vivax.Methodology/principal findings A 14-year follow-up study was carried out among long-term P. vivax-exposed Amazonian individuals (272, median age 35 years), and included 9 cross-sectional surveys at periods of high and low malaria transmission. The experimental approach focused on monitoring antibodies to the major blood-stage P. vivax vaccine candidate, the Duffy binding protein region II (DBPII-Sal1), including a novel engineered DBPII-based vaccine targeting conserved epitopes (DEKnull-2). In parallel, the status of EBV infection was determined over time by the detection of circulating EBV DNA (EBV-DNAemia) and EBV-specific antibodies to lytic (VCAp18) or latent (EBNA1) antigens. Regardless of the malaria transmission period, the results demonstrated that one or multiple episodes of EBV-DNAemia did not influence the longevity of DBPII immune responses to both strain-specific (Sal-1) or strain-transcending (DEKnull-2) antibodies. Also, the average time in which DBPII-responders lost their antibodies was unrelated to the EBV serostatus. Considering all malaria cases detected during the study, there was a predominance of P. vivax mono-infection (76%), with a positive association between malaria infection and detectable EBV-DNAemia.Conclusions/significance In an immunocompetent P. vivax-exposed adult population neither sporadic episodes of EBV-DNAemia nor antibody responses to lytic/latent EBV antigens influence the longevity of both strain-specific and strain-transcending DBPII immune responses. Further studies should investigate the role of acute P. vivax infection in the activation of EBV replication cycle.Competing Interest StatementThe authors have declared no competing interest.Funding StatementYesAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethical Committee of Research on Human Beings from the Rene Rachou Institute gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll relevant data are within the manuscript and its Supporting Information files.